Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-breaking analysis of its lead drug candidate vidofludimus calcium in patients with progressive multiple sclerosis. The late-breaking poster introduced a novel unified endpoint called Confirmed Disability Change, designed to capture both disability worsening and improvement within a single statistical framework.